



DR DEBORAH RATHJEN



Dr Deborah Rathjen is the CEO & Managing Director of Bionomics Limited, taking up her appointment with Bionomics on 19 June 2000, and recently renewing her contract till 2011.

Dr Rathjen has a Bachelor of Science (Honours) degree in biological sciences from Flinders University in Adelaide, and a PhD in Biology from Macquarie University, Sydney, in a joint program with the CSIRO.

Following post-doctoral studies at the Kolling Institute of Medical Research, she joined Peptech Limited in 1988 as a Senior Scientist and held a variety of positions there, including Business Development and Licensing.

Dr Rathjen was a co-inventor of Arana's TNF technology and leader of the company's successful defense of its key TNF patents against legal challenges by BASF, Centocor and other companies with anti-TNF products. Dr Rathjen has significant experience in company building and financing, mergers and acquisitions, therapeutic product research and development, and business development and licensing.

Dr Rathjen is an expert in the field of cell biology with specific expertise in inflammation, infection and cancer, in particular the cytokines and growth factors involved in those processes.

Dr Rathjen is a member of the Prime Minister's Science Engineering and Innovation Council, the NH&MRC's Human Genetics Advisory Committee and the Innovation Australia Board. Dr Rathjen was formerly Deputy Chair of the Australian Biotechnology Advisory Council.